ifosfamide has been researched along with Glial Cell Tumors in 10 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thirty-six patients previously treated with surgery, radiation therapy and chemotherapy with a nitrosourea for malignant supratentorial gliomas received a combination of ifosfamide, carboplatin and etoposide (ICE) at tumour progression." | 9.08 | Treatment of recurrent malignant supratentorial gliomas with ifosfamide, carboplatin and etoposide: a phase II study. ( Ameri, A; Delattre, JY; Monjour, A; Poisson, M; Ronchin, P; Sahmoud, T; Sanson, M, 1996) |
| "27 patients with recurrent high grade glioma following surgery and radiation therapy were treated with 100 mg/m2 cisplatin and 6 g/m2 ifosfamide per cycle, administered on days 1-3 in 4 week cycles, for a maximum of six cycles." | 9.08 | Phase II study on cisplatin and ifosfamide in recurrent high grade gliomas. ( Jansen, RL; Kros, JM; Loosveld, OJ; Ma, J; Schellens, JH; Sillevis Smit, PA; Tijssen, CC; van den Bent, MJ; Vecht, CJ; Verweij, J, 1998) |
| "Drug interference of ifosfamide and sodium 2-mercaptoethanesulphonate (MESNA) was studied in three malignant glioma cell cultures (HTZ-17, HTZ-209B, and HTZ-243) by a recently developed in vitro method for evaluation of multimodal treatment interactions." | 7.68 | In vitro studies on interaction of 4-hydroperoxyifosfamide and 2-mercaptoethanesulphonate in malignant gliomas. ( Apfel, R; Bogdahn, U; Dekant, A; Jäger, AH; Pfeufer, B, 1993) |
| "Radiochemotherapy involving cisplatinum-based polychemotherapy is more toxic than radiotherapy in combination with temozolomide." | 5.48 | Concurrent radiotherapy with temozolomide vs. concurrent radiotherapy with a cisplatinum-based polychemotherapy regimen : Acute toxicity in pediatric high-grade glioma patients. ( Bison, B; Bojko, S; Gielen, GH; Hoffmann, M; Kortmann, RD; Kramm, CM; Pietsch, T; Seidel, C; von Bueren, AO; Warmuth-Metz, M, 2018) |
| "Thirty-six patients previously treated with surgery, radiation therapy and chemotherapy with a nitrosourea for malignant supratentorial gliomas received a combination of ifosfamide, carboplatin and etoposide (ICE) at tumour progression." | 5.08 | Treatment of recurrent malignant supratentorial gliomas with ifosfamide, carboplatin and etoposide: a phase II study. ( Ameri, A; Delattre, JY; Monjour, A; Poisson, M; Ronchin, P; Sahmoud, T; Sanson, M, 1996) |
| "27 patients with recurrent high grade glioma following surgery and radiation therapy were treated with 100 mg/m2 cisplatin and 6 g/m2 ifosfamide per cycle, administered on days 1-3 in 4 week cycles, for a maximum of six cycles." | 5.08 | Phase II study on cisplatin and ifosfamide in recurrent high grade gliomas. ( Jansen, RL; Kros, JM; Loosveld, OJ; Ma, J; Schellens, JH; Sillevis Smit, PA; Tijssen, CC; van den Bent, MJ; Vecht, CJ; Verweij, J, 1998) |
| "Drug interference of ifosfamide and sodium 2-mercaptoethanesulphonate (MESNA) was studied in three malignant glioma cell cultures (HTZ-17, HTZ-209B, and HTZ-243) by a recently developed in vitro method for evaluation of multimodal treatment interactions." | 3.68 | In vitro studies on interaction of 4-hydroperoxyifosfamide and 2-mercaptoethanesulphonate in malignant gliomas. ( Apfel, R; Bogdahn, U; Dekant, A; Jäger, AH; Pfeufer, B, 1993) |
| "Dose-effect relations have been evaluated by the treatment of cell cultures (9L glioma cells of rat as monolayers and tumor spheroids, L 1210 cells of mice) with activated isophosphamide, adriamycin, epirubicin and 6 MeV electrons." | 3.68 | Biophysical aspects of the integrated combination of cytostatic drugs with radiotherapy. Part 2: Dose-effect relationships and 31P NMR spectroscopy of L 1210 cells (monolayers) and 9L glioma cells (monolayers and tumor spheroids) treated with activated is ( Ulmer, W, 1991) |
| "Radiochemotherapy involving cisplatinum-based polychemotherapy is more toxic than radiotherapy in combination with temozolomide." | 1.48 | Concurrent radiotherapy with temozolomide vs. concurrent radiotherapy with a cisplatinum-based polychemotherapy regimen : Acute toxicity in pediatric high-grade glioma patients. ( Bison, B; Bojko, S; Gielen, GH; Hoffmann, M; Kortmann, RD; Kramm, CM; Pietsch, T; Seidel, C; von Bueren, AO; Warmuth-Metz, M, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (60.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Seidel, C | 1 |
| von Bueren, AO | 1 |
| Bojko, S | 1 |
| Hoffmann, M | 1 |
| Pietsch, T | 1 |
| Gielen, GH | 1 |
| Warmuth-Metz, M | 1 |
| Bison, B | 1 |
| Kortmann, RD | 1 |
| Kramm, CM | 1 |
| Yano, Y | 1 |
| Kodawara, T | 1 |
| Hongo, H | 1 |
| Yano, I | 1 |
| Kishi, Y | 1 |
| Takahashi, J | 1 |
| Inui, K | 1 |
| Schäfer, N | 1 |
| Tichy, J | 1 |
| Thanendrarajan, S | 1 |
| Kim, Y | 1 |
| Stuplich, M | 1 |
| Mack, F | 1 |
| Rieger, J | 1 |
| Simon, M | 1 |
| Scheffler, B | 1 |
| Boström, J | 1 |
| Steinbach, JP | 1 |
| Herrlinger, U | 1 |
| Glas, M | 1 |
| Geyer, JR | 1 |
| Sposto, R | 1 |
| Jennings, M | 1 |
| Boyett, JM | 1 |
| Axtell, RA | 1 |
| Breiger, D | 1 |
| Broxson, E | 1 |
| Donahue, B | 1 |
| Finlay, JL | 1 |
| Goldwein, JW | 1 |
| Heier, LA | 1 |
| Johnson, D | 1 |
| Mazewski, C | 1 |
| Miller, DC | 1 |
| Packer, R | 1 |
| Puccetti, D | 1 |
| Radcliffe, J | 1 |
| Tao, ML | 1 |
| Shiminski-Maher, T | 1 |
| Jäger, AH | 1 |
| Bogdahn, U | 1 |
| Apfel, R | 1 |
| Pfeufer, B | 1 |
| Dekant, A | 1 |
| Heideman, RL | 1 |
| Douglass, EC | 1 |
| Langston, JA | 1 |
| Krischer, JP | 1 |
| Burger, PC | 1 |
| Kovnar, EH | 1 |
| Kun, LE | 1 |
| Friedman, HS | 1 |
| Kadota, R | 1 |
| Sanson, M | 1 |
| Ameri, A | 1 |
| Monjour, A | 1 |
| Sahmoud, T | 1 |
| Ronchin, P | 1 |
| Poisson, M | 1 |
| Delattre, JY | 1 |
| Urban, C | 1 |
| Benesch, M | 1 |
| Pakisch, B | 1 |
| Lackner, H | 1 |
| Kerbl, R | 1 |
| Schwinger, W | 1 |
| Oberbauer, R | 1 |
| van den Bent, MJ | 1 |
| Schellens, JH | 1 |
| Vecht, CJ | 1 |
| Sillevis Smit, PA | 1 |
| Loosveld, OJ | 1 |
| Ma, J | 1 |
| Tijssen, CC | 1 |
| Jansen, RL | 1 |
| Kros, JM | 1 |
| Verweij, J | 1 |
| Ulmer, W | 1 |
5 trials available for ifosfamide and Glial Cell Tumors
| Article | Year |
|---|---|
Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child, Preschool; Cisplatin; Combin | 2005 |
A phase II study of every other day high-dose ifosfamide in pediatric brain tumors: a Pediatric Oncology Group Study.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carcinoma; Child | 1995 |
Treatment of recurrent malignant supratentorial gliomas with ifosfamide, carboplatin and etoposide: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Etopo | 1996 |
Synchronous radiochemotherapy in unfavorable brain tumors of children and young adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Che | 1998 |
Phase II study on cisplatin and ifosfamide in recurrent high grade gliomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Female; Glioma; H | 1998 |
5 other studies available for ifosfamide and Glial Cell Tumors
| Article | Year |
|---|---|
Concurrent radiotherapy with temozolomide vs. concurrent radiotherapy with a cisplatinum-based polychemotherapy regimen : Acute toxicity in pediatric high-grade glioma patients.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Chil | 2018 |
Population analysis of myelosuppression profiles using routine clinical data after the ICE (ifosfamide/carboplatin/etoposide) regimen for malignant gliomas.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; | 2009 |
Ifosfamide, carboplatin and etoposide in recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carboplat | 2011 |
In vitro studies on interaction of 4-hydroperoxyifosfamide and 2-mercaptoethanesulphonate in malignant gliomas.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dr | 1993 |
Biophysical aspects of the integrated combination of cytostatic drugs with radiotherapy. Part 2: Dose-effect relationships and 31P NMR spectroscopy of L 1210 cells (monolayers) and 9L glioma cells (monolayers and tumor spheroids) treated with activated is
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biophysical Phenomena; Biophysics; Cell Lin | 1991 |